Skip to NavigationSkip to content

GSK to axe 99 positions at Memphis site

Published on 18/10/18 at 11:43am

GlaxoSmithKline’s workforce on President’s Island in Memphis, US, is set to see the loss of 99 employees, as revealed in a WARN notice filed with the State Department of Labor.

The reason for the layoffs originates in the expiry of a contract manufacturing agreement by January 2019, which the company confirmed it would not be renewing.

“Due to this business change, GSK has filed a WARN (Worker Adjustment and Retraining Notification Act) notice with the Tennessee Department of Labor, to inform that we currently anticipate that 99 employees will be displaced between December 2018 and April 2019,” said GSK spokeswoman Caryn Previdi.

Specifically, the cuts will come into effect from 10 December to 2 April, according to the company’s WARN notice. After the 99 roles have been axed, 160 positions will remain at the site.

“We have a loyal and committed workforce at our Memphis site and this decision is no reflection on the team or their performance,” Previdi continued. “Teams at the Memphis site have demonstrated a great level of commitment to the business and we very much appreciate their dedication and hard work.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches